The PK/PD Study of SHR2285 Tablets in Healthy Subjects

Inclusion Criteria: 1. males or females, aged 18-45 2. subjects with no cardiovascular disease, sitting blood pressure: 90mmHg ≤SBP\<140mmHg and 50mmHg ≤DBP\<90mmHg; 3. body mass index (BMI) between 18 to 28, and a total body weight: male ≥50.0 kg and \<90.0 kg; female ≥45.0 kg and \<90.0 kg 4. Participant in general good health. No clinically significant findings in laboratory parameters or clinically significant abnormality on X-ray Exclusion Criteria: 1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin \> 1X ULN during screening/baseline; 2. Abnormal coagulation function; 3. A clinical history of coagulation dysfunction；subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs. 4. Subjects with severe trauma or surgery within 3 months prior to the screening； 5. Known blood donation within 30 days pre-dose; donating≥400 ml of blood 3 months pre-dose; 6. Human immunodeficiency virus antibody (HIV-ab), syphilis serological examination, hepatitis b virus surface antigen (HBsAg), hepatitis c virus antibody (HCV-ab) were positive; 7. 3 months prior to screening involved in any drug or medical device clinical subjects, or within 5 half-life of drugs before screening; 8. Pregnant or Serum β-hCG \> 5mIU/mL at baseline or women who are breastfeeding; etc.